摘要
目的探讨lncRNA TRIM52-AS1在非小细胞肺腺癌组织中的表达及其临床意义。方法通过实时荧光定量PCR和WST-1等方法检测lncRNA TRIM52-AS1在肺腺癌组织与癌旁组织以及肺腺癌细胞株与正常支气管细胞株中的表达差异。在体外肺腺癌细胞中过表达lncRNA TRIM52-AS1,WST-1法及克隆形成实验检测其对细胞生长的影响。结果lncRNA TRIM52-AS1在肺腺癌组织中的表达水平显著低于癌旁正常组织(P<0.01);lncRNA TRIM52-AS1高表达患者的总生存期(OS)显著长于低表达患者(P<0.05);lncRNA TRIM52-AS1在肺腺癌细胞株中的表达水平显著低于正常支气管细胞株(P<0.05);过表达lncRNA TRIM52-AS1可抑制肺腺癌细胞的增殖与克隆能力(P<0.05)。结论lncRNA TRIM52-AS1具有抑制肺腺癌细胞生长的作用,可能作为治疗肺腺癌的潜在靶点之一。
Objective To investigate the expression and clinical significance of IncRNA TRIM52-AS1 in the tissues of lung cancer patients.Methods The expression of lncRNA TRIM52-AS1 in lung adenocarcinoma tissues and paracancer tissues as well as lung adenocarcinoma cell lines and normal bronchial cell lines were detected by real-time fluorescence quantitative PCR and WST1 methods.After IncRNA TRIM52-AS1 was overexpressed in lung adenocarcinoma cells in vitro,WST1 method and colony fornation assay were applied to detect the effects of overexpressed lncRNA TRIM52-AS1 on the cells.Results The expression of lncRNA TRIM52-AS1 in lung adenocarcinoma tissues was obviously decreased when compared with that in paracarcinoma tissues(P<0.01).Patients with high lncRNA TRIM52-AS1 expression had significant longer overall survival(OS)than those with low lncRNA TRIM52-AS1 expression(P<0.05).The expression level of lncRNA TRIM52-AS1 was lower in lung adenocarcinoma cell lines than in normal bronchial cell lines(P<0.05).Overexpression of lncRNA TRIM52-AS1 inhibited the proliferation and clone ability of lung adenocarcinoma cells(P<0.05).Conclusion lncRNA TRIM52-AS1 can inhibit the growth of lung adenocarcinoma cells and may be a potential target for the treatment of lung adenocarcinoma.
作者
邓义飞
武奋萍
薛建新
王峰
DENG Yifei;WU Fenping;XUE Jianxin;WANG Feng(Department of Thoracic Oncology/Cancer Center and State Key Laboratory of Biotherapy,West China Hospital,Sichuan University,Chengdu,Sichuan,610041,China;Department of Head and Neck Oncology,West China Hospital,Sichuan University,Chengdu,Sichuan,610041,China;Department of Radiation Oncology,Chengdu Seventh People’s Hospital,Chengdu,Sichuan,610041,China)
出处
《肿瘤药学》
CAS
2020年第1期40-45,共6页
Anti-Tumor Pharmacy
